Alaunos Therapeutics (TCRT) Net Income towards Common Stockholders (2009 - 2026)
Alaunos Therapeutics (TCRT) reported Net Income towards Common Stockholders of -$1.0 million for Q1 2026, up 7.33% on a YoY basis from -$942921.5 in Q1 2025, and down 11.58% quarter-over-quarter from -$907000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Alaunos Therapeutics has reported Net Income towards Common Stockholders for 18 years, with the latest figure at -$1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 7.33% year-over-year to -$1.0 million; the trailing twelve-month figure through Mar 2026 stood at -$4.1 million (changed 0.43% YoY), and the FY2025 full-year result was -$4.2 million, up 12.2% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$1.0 million, down from -$907000.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$755000.0 in Q4 2024, with the low at -$10.5 million in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged -$5.0 million across 5 years, with a median of -$1.7 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 90.5% — and 2025, when it slipped 20.13%.
- Alaunos Therapeutics' Net Income towards Common Stockholders stood at -$9.4 million in 2022, then advanced by 15.52% to -$7.9 million in 2023, then soared by 90.5% to -$755000.0 in 2024, then fell by 20.13% to -$907000.0 in 2025, then fell by 11.58% to -$1.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$1.0 million (Q1 2026), -$907000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | -1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.01 Mn |
| Dec 31, 2025 | -907,000.00 |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.04 Mn |
| Mar 31, 2025 | -1.09 Mn |
| Dec 31, 2024 | -755,000.00 |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -7.95 Mn |
| Sep 30, 2023 | -8.66 Mn |
| Jun 30, 2023 | -9.05 Mn |
| Mar 31, 2023 | -10.53 Mn |
| Dec 31, 2022 | -9.41 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.93 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -11.80 Mn |
| Sep 30, 2021 | -22.70 Mn |
| Jun 30, 2021 | -22.67 Mn |